Stay updated on GMI-1359 Safety in HR+ Metastatic Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the GMI-1359 Safety in HR+ Metastatic Breast Cancer Clinical Trial page.

Latest updates to the GMI-1359 Safety in HR+ Metastatic Breast Cancer Clinical Trial page
- Check3 days agoChange DetectedThe page's revision tag was updated from v3.6.4 to v3.6.5. This signals a minor update to the page's build or content.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedPage revision updated from v3.6.3 to v3.6.4, representing a new release of the page template/content. This appears to be a routine deployment without changes to study data or primary information.SummaryDifference0.1%

- Check24 days agoNo Change Detected
- Check39 days agoChange DetectedRevision: v3.6.3 was added and v3.6.2 removed, indicating a minor, system-wide update to the study record on ClinicalTrials.gov. This update does not alter the study content, eligibility criteria, or outcomes.SummaryDifference0.1%

- Check46 days agoChange DetectedThe page's revision stamp was updated from v3.6.0 to v3.6.2, indicating a newer version of the page. This update updates the page tracking without changing the study details presented.SummaryDifference0.1%

- Check60 days agoChange DetectedRecruitment status updated to no longer accept participants, and new user guidance sections were added (How to Read a Study Record, Common Questions, How to Join a Study). There is also a formatting update to the Intervention/Treatment label and the revision note changed from v3.5.5 to v3.6.0.SummaryDifference0.6%

- Check67 days agoChange DetectedThe page revision updated from v3.5.4 to v3.5.5. This indicates a minor internal update to the page version without changing the displayed study details.SummaryDifference0.1%

Stay in the know with updates to GMI-1359 Safety in HR+ Metastatic Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GMI-1359 Safety in HR+ Metastatic Breast Cancer Clinical Trial page.